Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Antonios Gkantaras has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Does CVID exist in children? A genetic architecture and manifestation map derived from 7,525 patients

    by Antonios Gkantaras, Esid Registry Working Party, Dalia Abd Elaziz, Sohilla Lofty M. Abdelkader, Avigaelle Abitbol, Hassan Abolhassani, Lalash Abrahim, Mohamed Abuzakouk, Pietro Andrea Accardo, Nabila Achir Moussouni, et al.

    Diagnosing common variable immunodeficiency (CVID) in childhood remains contentious, as monogenic inborn errors of immunity (IEIs) are increasingly recognized in CVID-like phenotypes. We analyzed 7,525 ESID Registry patients with a clinical diagnosis of CVID to investigate age-dependent genetic architecture and associated phenotypes. Among living CVID patients, monogenic defects were identified in 82 of 251 children younger than 18 years (32.7%) versus 447 of 5,225 adults (8.6%; OR: 5.18, 95% CI: 3.86–6.92). Pediatric-onset disease (<18 years) likewise demonstrated increased monogenic underpinnings (OR: 1.88, 95% CI: 1.56–2.27), strongest with onset before 4 years (OR: 2.99, 95% CI: 2.38–3.78). Monogenic “CVID” was more likely associated with immune dysregulation at presentation (OR: 1.98, 95% CI: 1.66–2.36) and negatively linked to infection-predominant manifestations (OR: 0.67, 95% CI: 0.56–0.81). Physician-entered “additional-gene” annotations suggested multigene constellations in 1.6% of patients and identified recurrently recorded variants in other IEI-associated genes, including TCF3, PIK3CD, and KMT2D, among unresolved cases. These findings support “pediatric CVID” as a provisional label requiring systematic genetic evaluation.

  • Open Access

    Fetal and Neonatal Immune Response to Congenital Cytomegalovirus (cCMV) Infection: A Systematically Conducted Scoping Review

    by Chrysanthi-Eleni Loizou, Antonios Gkantaras, Sofia Karagiannidou, Garyfallia Syridou, Despoina Gkentzi, Vassiliki Papaevangelou, Evangelia Farmaki

    Congenital Cytomegalovirus (cCMV) infection is associated with numerous long-term sequelae. This scoping review consolidates existing evidence on fetal and neonatal immune response to cCMV and their potential relevance to clinical outcomes. A systematic search was conducted in the PubMed database. Observational studies were eligible when full text was available in English and data for immune response (innate, humoral, cellular) and/or immune-related biomarkers (cytokines and molecular markers) were provided. Thirty-four studies were included. CMV-infected fetuses mount robust γδ and CD8+ T-cell responses from the second trimester of pregnancy, with the transcriptomic and cytokine profile of their amniotic fluid revealing upregulation of IFN-γ-inducible genes and cytokines. cCMV-infected neonates mount oligoclonal γδ T-cell responses and functional NK and CD8+ T-cell responses, although data on the latter’s association with symptoms at birth are contradictory. Conversely, CD4+ T-cell responses are impaired, irrespective of symptoms. T cell exhaustion is an emerging finding with unclear implications on long-term outcome. Despite shared transcriptomic profiles between symptomatic and asymptomatic neonates, a 16-gene classifier biosignature has been identified for late-onset sensorineural hearing loss. In conclusion, immune response to cCMV is characterized by a Th1 signature, with T cell exhaustion being an emerging finding warranting further investigation.

  • Open Access

    Targeted Next-Generation Sequencing in the Molecular Diagnosis of Severe Combined Immunodeficiency

    by Evangelos Bakaros, Styliani Sarrou, Antonios Gkantaras, Alexia Matziri, Achilleas P. Galanopoulos, Konstantina Charisi, Athanasios Bangeas, Anna Taparkou, Eleni Papadimitriou, Varvara A. Mouchtouri, et al.

    Background and Objectives: Severe combined immunodeficiency (SCID) represents a group of rare and potentially fatal monogenic disorders arising from pathogenic variants in a broad spectrum of genes. Diagnostic delays beyond the first few months of life have been associated with poor overall survival and hematopoietic stem cell transplantation (HSCT) outcomes. Therefore, the aim of our study was to apply an NGS assay enabling the rapid and reliable diagnosis of SCID. Materials and Methods: We developed a targeted NGS panel of 30 genes implicated in the pathogenesis of most SCID cases and we applied it to three Greek infants with suspected SCID. Results: Each patient displayed a distinct immunophenotype—T−B−NK−, T−B−NK+ and T−B+NK−, respectively—and was found to harbor pathogenic or likely pathogenic variants in the analyzed SCID-related genes. In particular, patient 1 carried two heterozygous ADA variants (c.58G>A, p.Gly20Arg and c.956_960del, p.Glu319Glyfs); patient 2 harbored two discrete pathogenic variants in the DCLRE1C gene (a large deletion of exons 1–3 and the nonsense mutation c.241C>T, p.Arg81*), causing Artemis deficiency; and patient 3 carried a hemizygous IL2RG missense variant (c.437T>C, p.Leu146Pro), associated with X-linked SCID. All variants were confirmed by Sanger sequencing. Conclusions: Our method successfully identified the underlying genetic defects in all patients, thereby establishing a molecular diagnosis of SCID. These findings highlight the potential of targeted NGS assays for achieving rapid and accurate molecular diagnosis of SCID, which is crucial for the timely treatment of life-threatening conditions in affected children.

  • Open Access

    Inborn errors of immunity: Manifestation, treatment, and outcome—an ESID registry 1994–2024 report on 30,628 patients

    by Gerhard Kindle, Mickaël Alligon, Michael H. Albert, Matthew Buckland, J. David Edgar, Benjamin Gathmann, Sujal Ghosh, Antonios Gkantaras, Alexandra Nieters, Claudio Pignata, et al.

    The European Society for Immunodeficiencies patient registry (ESID-R), established in 1994, is one of the world’s largest databases on inborn errors of immunity (IEI). IEI are genetic disorders predisposing patients to infections, autoimmunity, inflammation, allergies, and malignancies. Treatments include antimicrobial therapy, immunoglobulin replacement, immune modulation, stem cell transplantation, and gene therapy. Data from 194 centers in 33 countries capture clinical manifestations and treatments from birth onward, with annually expected updates. This report reviews the ESID-R’s structure, data content, and impact. The registry includes 30,628 patient datasets (aged 0–97.9 years; median follow-up: 7.2 years; total 825,568.2 patient-years), with 13,550 cases in 15 sub-studies. It has produced 84 peer-reviewed publications (mean citation rate: 95). Findings include real-world observations of IEI diagnoses, genetic causes, clinical manifestations, treatments, and survival trends. The ESID-R fosters global collaboration, advancing IEI research and patient care. This report highlights the key role of the multinational ESID-R, led by an independent medical society, in evidence-based discovery.


  • Open Access

    Inborn errors of immunity: manifestation, treatment, and outcome – an ESID registry 1994-2024 report on 30,628 patients

    by Gerhard Kindle, Mickaël Alligon, Michael H. Albert, Matthew Buckland, J. David Edgar, Benjamin Gathmann, Sujal Ghosh, Antonios Gkantaras, Alexandra Nieters, Claudio Pignata, et al.

    The European Society for Immunodeficiencies patient registry (ESID-R), established in 1994, is one of the world’s largest databases on inborn errors of immunity (IEI). IEI are genetic disorders predisposing patients to infections, autoimmunity, inflammation, allergies and malignancies. Treatments include antimicrobial therapy, immunoglobulin replacement, immune modulation, stem cell transplantation and gene therapy. Data from 194 centers in 33 countries capture clinical manifestations and treatments from birth onward, with annually expected updates. This report reviews the ESID-R’s structure, data content, and impact. The registry includes 30,628 patient datasets (aged 0–97.9 years; median follow-up: 7.2 years; total 825,568.2 patient-years), with 13,550 cases in 15 sub-studies. It has produced 84 peer-reviewed publications (mean citation rate: 95). Findings include real-world observations of IEI diagnoses, genetic causes, clinical manifestations, treatments, and survival trends. The ESID-R fosters global collaboration, advancing IEI research and patient care. This report highlights the key role of the multi-national ESID-R, led by an independent medical society, in evidence-based discovery. Summary: Worldwide, most patient registries for inborn errors of immunity are national, with limited geographical and temporal scope. This 30-year ESID registry analysis of 30,628 patients’ longitudinal datasets enables robust epidemiological studies on natural disease courses including diagnosis, treatment, and survival, supporting expanded newborn screening and future AI applications in IEI research.


  • Open Access

    Multi-Cohort Transcriptomic Profiling of Medical Gas Plasma-Treated Cancers Reveals the Role of Immunogenic Cell Death

    by Antonios Gkantaras, Charalampos Kotzamanidis, Konstantinos Kyriakidis, Evangelia Farmaki, Kali Makedou, Georgios Tzimagiorgis, Sander Bekeschus, Andigoni Malousi

    The therapeutic potential of cold physical gas plasma operated at atmospheric pressure in oncology has been thoroughly demonstrated in numerous preclinical studies. The cytotoxic effect on malignant cells has been attributed mainly to biologically active plasma-generated compounds, namely, reactive oxygen and nitrogen species. The intracellular accumulation of reactive oxygen and nitrogen species interferes strongly with the antioxidant defense system of malignant cells, activating multiple signaling cascades and inevitably leading to oxidative stress-induced cell death. This study aims to determine whether plasma-induced cancer cell death operates through a universal molecular mechanism that is independent of the cancer cell type. Using whole transcriptome data, we sought to investigate the activation mechanism of plasma-treated samples in patient-derived prostate cell cultures, melanoma, breast, lymphoma, and lung cancer cells. The results from the standardized single-cohort gene expression analysis and parallel multi-cohort meta-analysis strongly indicate that plasma treatment globally induces cancer cell death through immune-mediated mechanisms, such as interleukin signaling, Toll-like receptor cascades, and MyD88 activation leading to pro-inflammatory cytokine release and tumor antigen presentation.


  • Open Access

    Histological Alterations in Hashimoto’s Disease: A Case-Series Ultrastructural Study

    by Eleni Avramidou, Antonios Gkantaras, Iasonas Dermitzakis, Konstantinos Sapalidis, Maria Eleni Manthou, Paschalis Theotokis

    Background: Hashimoto’s thyroiditis (HT) is an autoimmune disease exhibiting stromal fibrosis and follicular cell destruction due to lymphoplasmacytic infiltration. Besides deprecated analyses, histopathological approaches have not employed the use of electron microscopy adequately toward delineating subcellular-level interactions. Methods: Biopsies for ultrastructural investigations were obtained from the thyroids of five patients with HT after a thyroidectomy. Transmission electron microscopy (TEM) was utilized to study representative tissue specimens. Results: Examination indicated interstitial extravasated blood cells and a plethora of plasma cells, based on their subcellular identity landmarks. These antibody-secreting cells were profoundly spotted near follicular cells, fibroblasts, and cell debris entrenched in collagenous areas. Pathological changes persistently affected subcellular components of the thyrocytes, including the nucleus, endoplasmic reticulum (ER), Golgi apparatus, mitochondria, lysosomes, and other intracellular vesicles. Interestingly, significant endothelial destruction was observed, specifically in the larger blood vessels, while the smaller vessels appeared comparatively unaffected. Conclusions: Our TEM findings highlight the immune-related alterations occurring within the thyroid stroma. The impaired vasculature component and remodeling have not been described ultrastructurally before; thus, further exploration is needed with regards to angiogenesis in HT in order to achieve successful prognostic, diagnostic, and treatment-monitoring strategies.


  • Open Access

    Mannitol Challenge to Assess Therapy Response in Asthmatic Children: An Interventional Cohort Study

    by Nikolaos Karantaglis, Fotios Kirvassilis, Elpis Hatziagorou, Antonios Gkantaras, Kalliopi Kontouli, John Tsanakas, Maria Emporiadou

    Bronchial provocation tests, such as the mannitol challenge, can be performed to identify and quantify the severity of bronchial hyperresponsiveness in asthmatic patients. Studies of the mannitol challenge as a monitoring tool in asthmatic children are limited. Our primary aim was to compare the bronchial hyperresponsiveness to mannitol in treatment-naive asthmatic children between baseline and three months after receiving the indicated asthma prophylaxis. Twenty-three asthmatic patients aged 4–16 years were analyzed in this prospective cohort study. All subjects underwent the mannitol challenge at baseline and after three months of treatment with budesonide ± formoterol. The difference in the provocative dose of mannitol to induce a 15% drop in FEV1 (PD15) between baseline and follow-up, as well as its association with the presence of exercise-induced or nocturnal asthma symptoms, were evaluated. The PD15 value increased significantly post-treatment (228.5 mg [4.50–458.15]; p = 0.04). Independently of the evaluation time point, the PD15 values were significantly lower in the presence of nocturnal asthma symptoms (490 mg [122–635] vs. 635 mg [635–635]; p = 0.03), whereas there was no association between the PD15 value and the presence of exercise-induced asthma (p = 0.73). These results suggest that bronchial hyperresponsiveness to mannitol may be a potential monitoring tool in the pediatric asthmatic population, reflecting therapy response in children receiving prophylactic treatment.


  • Evidence and rationale for vaccinating children and adolescents against SARS-CoV-2: a comprehensive narrative review

    by Nikolaos Karantaglis, Antonios Gkantaras, Despoina Iordanidou, Eleni Volakli, Eleni Karakeke, Maria Katsafiloudi, Asimina Violaki, Maria Sdougka

    Vaccines remain the most rigorous and cost-effective weapon of the public health care system against infectious diseases. The development of safe and effective vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged as an imperative response to the unprecedented morbidity and mortality of the Coronavirus Disease 2019 (COVID-19) pandemic and the subsequent immense pressure on health care systems, families and global society. Despite the typically mild disease course of SARS-CoV-2 in minors, the associated rare but potentially life-threatening complications, as well as the emergence of new highly transmissible variants, led promptly to the extension of COVID-19 vaccine clinical trials in children and adolescents. To date, various COVID-19 vaccine candidates have been successfully trialed in pediatric populations, followed by their incorporation into corresponding vaccination campaigns in both high- and low-income countries. However, the universal COVID-19 vaccination of children and adolescents remains a matter of debate, along with skepticism about their overall safety and benefits in this age group. In this narrative review, we attempt to summarize the multi-faceted burden of COVID-19 on minors, highlighting the favourable safety/effectiveness profile of COVID-19 vaccines in this age group, elucidating the raised concerns and presenting the current implemented vaccination strategies.